Metabolic stability studies indicated valproates metabolism is not primarily eliminated through CYP450, suggesting that the in vivo interaction likely results from inhibition of -oxidation or glucuronidation
While care has been taken in the production of this document, Aon does not warrant, represent or guarantee the accuracy, adequacy, completeness or fitness for any purpose of the document or any part of it and can accept no liability for any loss incurred in any way by any person who may rely on it
If you suspect a quality issue, discussing alternative sources with your provider is warranted
Rev Endocr Metab Disord 15(3):181187 van Bloemendaal L et al (2014) GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans
Victoza is an older GLP-1 drug made by Novo Nordisk (NYSE:NVO), maker of semaglutide, the active ingredient in Ozempic and Wegovy
A peer-reviewed overview of sermorelin in adults is available through the National Library of Medicine